Oregon Health Plan

Schrödinger Highlights Progress of Clinical Programs and Discloses Three New Programs at First Therapeutics Pipeline Investor Event

Retrieved on: 
Thursday, December 14, 2023
Software, Research, General Health, Pharmaceutical, Medical Devices, Technology, Genetics, Clinical Trials, Science, Biotechnology, Other Science, Health, CNS, Safety, CDC7, Bone marrow, Lymphoid leukemia, Acute myeloid leukemia, ASH, IND, Syndrome, Pipeline, Brain, Patient, Neurology, Lung cancer, PRMT5, Neoplasm, Therapy, Oregon Health Plan, Toxic encephalopathy, MALT1, AML, NLRP3, Society, Myelodysplastic syndrome, EGFR, Outline, Pharmaceutical industry, Vaccine

The data support continued evaluation of SGR-1505 in the ongoing Phase 1 study in patients with relapsed or refractory B-cell malignancies.

Key Points: 
  • The data support continued evaluation of SGR-1505 in the ongoing Phase 1 study in patients with relapsed or refractory B-cell malignancies.
  • “These data add significantly to our understanding of SGR-1505 and inform our clinical development strategy in hematologic malignancies.
  • Schrödinger is presenting three new proprietary discovery programs at Pipeline Day, targeting EGFRC797S, PRMT5-MTA and NLRP3.
  • Schrödinger is advancing multiple oncology programs designed to exploit the intrinsic vulnerabilities of cancer cells through synthetic lethality and inhibition of DNA-damage repair.

Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older

Retrieved on: 
Tuesday, September 12, 2023
PDE4, Flare, Disease, Irritant, Prevalence, Week, Oregon Health & Science University, Ethanol, Dermatitis, Parent, George Washington University School of Engineering and Applied Science, New Drug Application, George Washington University School of Medicine & Health Sciences, Propylene glycol, Skin, Atopic dermatitis, FAAD, Excipient, Oregon Health Plan, IGA, MCR, Shanda, MD, Patient, Risk, SUNY Downstate Health Sciences University, Outline of health sciences, AD, FDA, MPH, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Success, Vaccine, Pharmaceutical industry, Dermatology, Doctor of Philosophy

In clinical studies, once-daily roflumilast cream provided rapid clearance of the disease.

Key Points: 
  • In clinical studies, once-daily roflumilast cream provided rapid clearance of the disease.
  • Roflumilast cream is uniquely formulated with HydroARQ Technology™ as a non-greasy emollient cream that absorbs quickly and does not disrupt the skin barrier.
  • “Topical roflumilast cream was intentionally formulated with the atopic dermatitis patient in mind, and does not contain excipients that disrupt skin-barrier integrity or are common contact allergens.
  • I would like to thank the team at Arcutis for their incredible hard work and dedication,” added Watanabe.

Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD)

Retrieved on: 
Thursday, September 7, 2023
PDE4, Maintenance, Eczema Area and Severity Index, Irritant, Icahn School of Medicine at Mount Sinai, Week, Oregon Health & Science University, New Drug Application, COVID-19, Skin, Atopic dermatitis, Doctor of Philosophy, FAAD, Incidence, Excipient, Oregon Health Plan, IGA, MCR, Shanda, MD, Patient, Nature, Child, Common, Trinity Medical Sciences University, Mount, Immunology, Headache, Safety, Conditional sentence, Disease, Vaccine, Cosmetics, Dermatology

In the study, roflumilast cream was well-tolerated, with no new safety signals observed during treatment up to 56 weeks in duration.

Key Points: 
  • In the study, roflumilast cream was well-tolerated, with no new safety signals observed during treatment up to 56 weeks in duration.
  • Starting at Week 4 of INTEGUMENT-OLE, participants who achieved a vIGA-AD score of clear (0) switched to twice weekly maintenance dosing.
  • Participants were to resume once-daily dosing if vIGA-AD reached mild (2) or if signs or symptoms were not adequately controlled.
  • “Roflumilast cream is uniquely formulated to deliver treatment without sensitizing excipients and irritants, which can often disrupt the skin barrier.

AHN Opens New Precision Medicine and Developmental Therapeutics Cancer Clinic at AGH

Retrieved on: 
Thursday, September 7, 2023
Allegheny, Telehealth, University, Cancer Institute, American Board of Internal Medicine, Personalized medicine, Cancer, Development of the human body, Multimedia, Allegheny General Hospital, MS, American Board of Commissioners for Foreign Missions, Oregon Health Plan, Allegheny Health Network, National Cancer Center, Protein, Medical director, AHN, Patient, Physician, Walter Reed National Military Medical Center, Internal medicine, Medicine, Ponce Health Sciences University, Oncology, FDA, Health, Empowerment, Knight Cancer Institute, Disease, Hospital, Pharmaceutical industry, Medical imaging, MD

PITTSBURGH, Sept. 7, 2023 /PRNewswire-PRWeb/ -- The Allegheny Health Network Cancer Institute (AHNCI) announced today that it has established one of the region's first clinics dedicated to precision cancer medicine and has appointed nationally recognized medical oncologist Ariel Lopez-Chavez, MD, MS, to serve as director of the new clinic.

Key Points: 
  • The AHNCI's Precision Medicine and Developmental Therapeutics Clinic focuses on serving adults with metastatic solid tumors, and patients who may need second opinions or are seeking novel treatment options for rare, complex, or advanced-stage cancers.
  • The clinic is based at the AHN Cancer Institute at Allegheny General Hospital in Pittsburgh's North Side and offers both in-person and telemedicine appointments to patients.
  • Because every cancer patient has unique characteristics and preferences, a unique genetic profile, and because cancer is a dynamic, heterogeneous disease, precision therapies are considered the next frontier of cancer treatment.
  • As director of the Precision Medicine and Developmental Therapeutics Clinic, Dr. Lopez-Chavez will lead an innovative program that offers cancer patients access to clinical research trials and novel technologies aimed at maximizing cancer recovery and improving their overall well-being.

SimplePractice Announces Strategic Purchase of Assets of Luminello

Retrieved on: 
Thursday, August 3, 2023
Technology, Mental Health, Software, Practice Management, Networks, Health, Pharmaceutical, General Health, Data Management, Practice management, Growth, Oregon Health Plan, MD, Psychiatry, NYSE, Mental health, Patient, Face, Nursing

“We are thrilled to work closely with the Luminello team who support this critical segment of the mental health market.

Key Points: 
  • “We are thrilled to work closely with the Luminello team who support this critical segment of the mental health market.
  • We are excited about the opportunity to bring the value of SimplePractice to this important segment and we look forward to bringing the benefits of SimplePractice to Luminello's customers,” said SimplePractice President Jonathan Seltzer.
  • By offering a greater range of functionality for its growing practitioner base, SimplePractice expects to accelerate growth with multi-disciplinary group practices.
  • “Both SimplePractice and Luminello were founded by clinicians looking to simplify the business of running an independent solo or small group mental health practice,” said Ken Braslow, MD, Founder, Luminello.

Lumiant acquires Genivity to guide clients on lifestyle, longevity, and legacy choices

Retrieved on: 
Wednesday, April 26, 2023
Software, Personal Finance, Human Resources, Finance, Consulting, Professional Services, Technology, Fintech, Life, Disability, Oregon Health Plan, Risk, Retirement, Dream, Acquisition, HALO, Longevity, Health, GameChanger, Financial adviser, Sales, Genival Lacerda

“Lumiant aims to be the central location for clients to discover, plan and track their best lives.

Key Points: 
  • “Lumiant aims to be the central location for clients to discover, plan and track their best lives.
  • This means combining the core pillars of financial planning - lifestyle, legacy and now longevity - to provide clients with a holistic view of their overall wellbeing.
  • “Both Lumiant and Genivity offer new ways to engage clients outside of their finances, focusing on delivering an experience that connects with the client, rather than a mere service.
  • “The Genivity business effectively doubles down on the Lumiant proposition of helping people lead better lives, not selling them better products.

Kibur Medical Presents a Rational Approach to Identify Novel Combinations as Potential Immuno-oncology Therapies at the American Academy of Cancer Research in Orlando, FL

Retrieved on: 
Thursday, April 6, 2023
Charles River Laboratories, AACR, Kidney cancer, CDX, Syngenic, GEMM, Annual International Exhibition, Booth, American Academy, Gordon Mills, PDX, Spatial analysis, Oregon Health Plan, Brigham, Drug combination, Northwestern Health Sciences University, Poster, Hospital, FDA, Tumor microenvironment, Oregon Health & Science University, Breast cancer, Pharmaceutical industry

BOSTON, April 6, 2023 /PRNewswire-PRWeb/ -- Kibur Medical Inc., a Boston, MA - based company with a vision to close the translational gap in next generation cancer therapies, will present two posters at the upcoming American Academy of Cancer Research (AACR) annual meeting in April describing immune-oncology applications of the Kibur technology. Their innovative, tumor-implanted, drug-eluting microdevice evaluates up to twenty different compounds in vivo, to assess patient-specific combination therapies. The proprietary FDA approved-technology enables evidenced-based analyses of Phase 0 first in human studies and pre-clinical studies in CDX, syngeneic, xenograft, GEMM & PDX tumor models.

Key Points: 
  • Their innovative, tumor-implanted, drug-eluting microdevice evaluates up to twenty different compounds in vivo, to assess patient-specific combination therapies.
  • The proprietary FDA approved-technology enables evidenced-based analyses of Phase 0 first in human studies and pre-clinical studies in CDX, syngeneic, xenograft, GEMM & PDX tumor models.
  • "This work furthers our mission to transform cancer care and advance precision medicine for better patient outcomes."
  • Following the AACR annual meeting, Kibur is both sponsoring and hosting panel sessions at the 4th Annual International Phase-0/Microdosing Stakeholder Meeting on April 24th in Boston.

Stork Club launches maternity program with clinical study showing significant reduction in preterm births and unnecessary C-sections

Retrieved on: 
Wednesday, March 22, 2023
Insurance, Stork Club, Medicaid, Pregnancy, Doula, Employment, Research, Blog, Person, Associate, IVF, CDC, Oregon Health Plan, Journal, JOEM, Journal of Occupational and Environmental Medicine, SAN, Child, Northwestern Health Sciences University, Disease, Mortality, BIPOC, Health, ROI, Apgar, Environmental medicine, Nightclub, Birth control

Stork Club is the first provider in the US to offer managed birth doula care under employer-sponsored health plans.

Key Points: 
  • Stork Club is the first provider in the US to offer managed birth doula care under employer-sponsored health plans.
  • Given their commitment to cost-effective, evidence-based care, Stork Club also announced the results of the study, currently under peer review in a leading academic journal, indicate that Stork Club doula care was associated with a 45% reduction in unnecessary c-sections and a 58% reduction in preterm births compared to national averages.
  • A study of Stork Club's program shows a substantial reduction in preterm births and unnecessary C-sections, resulting in lower overall maternity care costs.
  • Based on the study's results, birthing persons who used Stork Club Birth Doula care experienced 45% fewer Cesarean births and 58% fewer preterm births (vs.

Virgin Pulse Helps Health Plans Reach Vulnerable Populations Facing Medicaid Redetermination

Retrieved on: 
Tuesday, February 14, 2023
Pew Research Center, Organization, Centers for Medicare & Medicaid Services, Medicaid, Schuylkill and Susquehanna Navigation Company, CHIP, Ebook, Mobile, EVP, Pulse, System, IVR, Virgin Group, Risk, Oregon Health Plan, CMS, Multimedia, Public, COVID-19, Activate, GM, Pharmaceutical industry

PROVIDENCE, R.I., Feb. 14, 2023 /PRNewswire/ -- A potential 15 million Americans are at risk of losing their healthcare coverage when the Medicaid Continuous Enrollment Requirement expires on March 31, 2023. Engaging Medicaid members is a long-standing challenge for health plans, and recertifying them (called redetermination) has not been required since early 2020 when the U.S. public health emergency created by COVID-19 began. Virgin Pulse, the leading global digital-first health, wellbeing, and navigation company, provides the data-driven, multi-channel technology that aligns with Centers for Medicare & Medicaid Services (CMS) guidance for communicating with members for redetermination. Currently working with health plans across the country, the company has launched a free multimedia toolkit to guide and support executives as they prepare to tackle Medicaid redetermination.

Key Points: 
  • Engaging Medicaid members is a long-standing challenge for health plans, and recertifying them (called redetermination) has not been required since early 2020 when the U.S. public health emergency created by COVID-19 began.
  • Currently working with health plans across the country, the company has launched a free multimedia toolkit to guide and support executives as they prepare to tackle Medicaid redetermination.
  • However, the reality is that health plans do not have the technology or expertise in-house to reach all these members to this extent," said Salem Shunnarah, EVP and GM, Health Plans and Systems for Virgin Pulse.
  • Virgin Pulse has curated a toolkit of free resources to inform health plan leaders about how to best plan for Medicaid redetermination and effectively reach members.

Cascade Health Alliance Partners with Valera Health to Bring Virtual Behavioral Healthcare to Oregonians

Retrieved on: 
Monday, January 23, 2023
Access, Serious mental illness, BIPOC, Entrepreneurship, Case management (mental health), Valera, Practitioner, Partnership, Oregon Health Plan, CHA, Health equity, SMI, Health, Medicaid, Patient, Anxiety, Depression, Mental health, Nursing, Hospital

NEW YORK, Jan. 23, 2023 /PRNewswire/ -- Valera Health, a telebehavioral health service that provides personalized team-based clinical care, has partnered with Cascade Health Alliance (CHA) to expand access of high-quality virtual behavioral healthcare services to individuals in Oregon.

Key Points: 
  • Valera Health's Platform Meets Growing Need for Access to Quality, Affordable Mental Health Services
    NEW YORK, Jan. 23, 2023 /PRNewswire/ -- Valera Health , a telebehavioral health service that provides personalized team-based clinical care, has partnered with Cascade Health Alliance (CHA) to expand access of high-quality virtual behavioral healthcare services to individuals in Oregon.
  • "We are excited about our partnership with Valera Health, that will result in increased health equity and health access among our members.
  • People will be able to access quality behavioral health care from virtually anywhere," says Tayo Akins, CEO, Cascade Health Alliance.
  • Cascade Health Alliance (CHA) was founded in 1992 to create health care access for Klamath County residents.